

# **HHS Public Access**

Author manuscript *J Pediatr Urol.* Author manuscript; available in PMC 2023 October 01.

Published in final edited form as:

J Pediatr Urol. 2022 October ; 18(5): 614.e1-614.e10. doi:10.1016/j.jpurol.2022.08.022.

# Association between age of starting clean intermittent catheterization and current urinary continence in individuals with myelomeningocele

Kurt A. Freeman<sup>a,\*</sup>, Tiebin Liu<sup>b</sup>, Kathryn Smith<sup>c</sup>, Heidi Castillo<sup>d</sup>, Jonathan Castillo<sup>d</sup>, David Joseph<sup>e</sup>, Yinding Wang<sup>b,f</sup>, Stacy Tanaka<sup>g,1</sup>

<sup>a</sup>Institute on Development and Disability, Department of Pediatrics, Oregon Health & Science University, 707 SW Gaines, Portland, OR 97239, USA

<sup>b</sup>Rare Disorders and Health Outcomes Team, Birth Defects Monitoring and Research Branch, Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention 4770 Buford Hwy, Mail StopS106-3, Chamblee, GA 30341-3717, USA

<sup>c</sup>Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, 4650 Sunset Blvd., Mailstop 53, Los Angeles, CA 90027, USA

<sup>d</sup>Developmental Pediatrics, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, 8080 North Stadium Drive, Suite 150, Houston, TX 77054, USA

<sup>e</sup>Department of Urology, School of Medicine, University of Alabama at Birmingham 1600 7th Avenue, South, ACC 318, Birmingham, AL 35233-1711, USA

<sup>f</sup>McKing Consulting Corporation, Atlanta, GA 2900 Chamblee Tucker Rd #10, Chamblee, GA 30341, USA

<sup>9</sup>Departments of Urology and Pediatrics, Vanderbilt University Medical Center, 2200 Children's Way, 4102 DOT, Nashville, TN 37232, USA

# Summary

**Introduction**—Patients with myelomeningocele often use clean intermittent catheterization (CIC) for renal preservation and to promote urinary continence. While starting CIC at an early age is associated with better renal outcomes, the impact of age of CIC initiation on continence outcomes has not been examined.

**Objective**—To examine whether earlier CIC initiation is associated with higher likelihood of current urinary continence for patients with myelomeningocele.

<sup>1</sup>Present Address: Children's Hospital of Alabama, 1600 7th Avenue, South, ACC 318, Birmingham, AL 35233-1711, USA. Appendix A. Supplementary data

<sup>&</sup>lt;sup>\*</sup>Correspondence to: Kurt A. Freeman, Oregon Health & Science University 707 SW Gaines Portland, OR 97239, USA, Fax: +503 494 6868, freemaku@ohsu.edu (K.A. Freeman). <sup>1</sup>Present Address: Children's Hospital of Alabama, 1600 7th Avenue, South, ACC 318, Birmingham, AL 35233-1711, USA.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jpurol.2022.08.022.

Conflicts of interest

The authors declare no conflict of interests. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

**Study design**—Data of patients aged 5 years at last visit were obtained from 35 spina bifida clinics participating in the National Spina Bifida Patient Registry from 2013 to 2018. Sociodemographic characteristics, disease characteristics, and current bladder management strategies were collected. Via univariate and multiple logistic regression models, the latter conducted controlling for all variables associated with current continent status, associations between continence and sociodemographic factors, condition characteristics, and age CIC began (<3 years of age, 3–5 years, 6–11 years, 12 years) were analyzed.

**Results**—Data from 3510 individuals were included (mean age at last visit = 17.0 years, range 5.0–88.7). The sample was evenly distributed by sex (52% female); most individuals were non-Hispanic White (62.6%). The majority of patients (55.2%) started CIC before age 3 years. Continence varied markedly across those who never started CIC (0.6% of patients were continent) and those who started at any age (range 35.3–38.5%). Among those who started CIC, the magnitude of the association was not proportional to age CIC was started. Compared with those who started CIC at age 12 or older, estimated adjusted odds ratio of being continent ranged from 1.04 (6–11 years, 95% CI, 0.72–1.52) to 1.25 (<3 years, 95% CI, 0.89–1.76).

**Discussion**—Although CIC may be positively associated with achieving urinary continence in individuals with myelomeningocele, we could not demonstrate that younger age at CIC initiation increased the likelihood of achieving this goal. Limitations include lack of data on reason for starting CIC, urodynamic data, and the observational nature of data collection.

**Conclusions**—Further study is needed addressing limitations of the current investigation to determine if urinary continence outcomes are influenced by the age of starting CIC among patients with myelomeningocele.

#### Keywords

Myelomeningocele; Urinary continence; Clean intermittent catheterization

Summary of univariate and multiple logistic regressions of age of initial CIC on bladder continence outcome. The National Spina Bifida Patient Registry, 2013-2018 (N = 3510, Age mean = 17.0 years, range 5.0-88.7)

Variables	Crude Odds Ratio (95% CI)	P-value	Adjusted Odds Ratio (95% CI) <sup>a</sup>	P-value
Age of initial CIC		0.67 <sup>b</sup>		0.1693 <sup>b</sup>
12 and older <sup>a</sup>				
6 to 11	0.95 (0.67–1.36)	0.80	1.04 (0.72–1.52)	0.83
3 to 5	0.87 (0.62–1.23)	0.43	1.05 (0.73–1.52)	0.78
Younger than 3	0.98 (0.72–1.34)	0.90	1.25 (0.89–1.76)	0.20

<sup>a</sup>Reference group.

<sup>b</sup>Overall p-value.

### Introduction

Neurogenic bladder is pervasive in spina bifida (SB), particularly its most common form, myelomeningocele [1-3], making it difficult to achieve continence despite advances in

medical and surgical interventions [4]. Extant research provides discrepant estimates of bladder incontinence in people with SB due to variations in continence definitions and data collection methods [5]. However, bladder incontinence is often present in well over half of individuals with SB [2-4,6]. Various sociodemographic (e.g., age, sex, race) and condition-specific (e.g., SB type, functional level of lesion) variables are associated with urinary incontinence [2,7].

Following its introduction in the 1970s, clean intermittent catheterization (CIC) has become standard for many individuals with neurogenic bladder. Benefits of CIC on renal preservation are well established [8-10]. Further, starting CIC before 3 years of age may result in better renal outcomes [11]. However, evidence regarding impact on continence outcomes is less robust. Use of CIC improves continence [4,12-14], although complete continence is not always achieved. There is some evidence that initiating bladder training earlier leads to better outcomes [15]. To date we are unaware of any study that has examined impact of age of starting CIC on continence outcomes.

Based on limited previous research about the impact of bladder interventions on continence, we hypothesized that earlier CIC initiation would be associated with higher likelihood of current urinary continence.

### Materials and methods

Data were obtained from 35 comprehensive SB clinics participating in the National Spina Bifida Patient Registry (NSBPR) from October 2013 through February 2018. Detailed description of the registry has been previously published [16]. Briefly, to participate in the registry, clinics must be multidisciplinary, commit to collecting standardized data on specific interventions and outcomes, and have cared for at least 250 patients with SB in the year prior to applying for inclusion. Patients of all ages are eligible for NSBPR enrollment. At the time of collection of data used in this analysis, clinics were expected to attempt to enroll all eligible participants.

The Institutional Review Board at registry sites approved procedures for the NSBPR. Patients or their legal guardians provided informed consent; youth assent was obtained when appropriate. Those diagnosed with myelomeningocele, lipomeningocele, meningocele, fatty filum, split cord malformation, and terminal myelocystocele are included in the registry. Baseline demographic and diagnostic information was collected at enrollment, and updated demographic and clinical data were gathered at annual visits. Individual data used in the current study are from the most recent clinic visit, obtained through a combination of medical chart review and patient interview.

#### Participant, condition, sociodemographic, and intervention variables

Only participants with myelomeningocele who responded to the prompt "Age at which CIC was started", were 5 years of age or older at the time of their last visit, had bladder impairment, and whose data were collected with NSBPR Version 2 were included in this analysis. The age of 5 years has consistently been used as the floor when examining continence outcomes with NSBPR data [2,7,17].

Although uncommon, some individuals with myelomeningocele do not experience neurogenic bladder. Grouping together individuals with and without bladder impairment risks masking outcome differences due to disease characteristic variations. Thus, segregating individuals with and without this impairment is important. NSBPR methods do not allow for objective determination of bladder impairment. Therefore, individuals aged five years and older who were continent without intervention were classified as having "no bladder impairment" and those using current bladder management strategies (scheduled void [yes/ no], scheduled catheterization [yes/no], and/or bladder medications [yes/no]) were defined as having "bladder impairment" [3]; only those with impairment were included.

Based on previous research [2,3,7], condition specific variables included in analyses are functional level of lesion (thoracic, high-lumbar, mid-lumbar, low-lumbar, and sacral, based on each lower extremity and classified by the more severe side), ambulation status (community ambulator, household ambulator, therapeutic ambulator, nonambulator) [18], and presence of hydronephrosis.

Sociodemographic variables included age at last visit, sex, race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic/Latino, and Other), insurance type (private, non-private) and highest educational level achieved.

Finally, to control for the influence of other interventions, data were included on current bladder management strategies (scheduled void/catheterization [yes/no], bladder medications [yes/no]), and history of urologic surgeries [yes/no] (a list of bladder medications prescribed and urologic surgeries tracked in the NSBPR are listed in Appendix I).

#### **Urinary continence**

Urinary continence at last visit was classified based on the following item, "Quantify frequency of urinary incontinence during the day over the last month (when not having a urinary tract infection)". Response options included: (a) patient and/or caregiver unable to provide information; (b) greater than or equal to once per day (daily); (c) less than once per day, greater than or equal to once per week (weekly); (d) less than once per week, greater than or equal to once per month (monthly); (e) less than once per month (less than monthly) and (f) never. Answers of "never" or "less than once per month" were considered as continent; this continence definition has been used with other studies using NSBPR data [17,19,20]. Patients with one of several forms of bladder management were excluded from analyses if they answered in a manner consistent with the study's definition of being continent, consistent with other NSBPR research [17]: urostomy bag, vesicostomy, indwelling catheter and condom catheter. Those who responded "Unable to provide information" were also excluded from the analysis.

#### Age of starting CIC

Patients or their legal guardians indicated age at which CIC was started based on pre-defined categories that were grouped as follows: never, younger than 3 years of age, 3–5 years, 6–11 years, and 12 years and older.

#### **Statistical analysis**

Associations between categorical variables and categories of age CIC began were examined in bivariate analysis by chi-square test as appropriate. Among patients who started CIC, we performed univariate and multiple logistic regression models to analyze associations between continence and patient sociodemographic factors, categories of age CIC began, and condition characteristics. Regarding categories of age CIC began, first analyses were conducted including all categories. Then, because patients with SB who start CIC prior to age 3 are most likely doing so due to renal factors rather than for continence purposes [21], secondary analyses were conducted excluding the "<3 years of age" category. Estimated odds ratios are presented with 95% confidence intervals. Data management and analyses were replicated and verified by a secondary analyst.

## Results

#### Demographics

Data from 3510 individuals with myelomeningocele aged 5 years and older (Mean = 17.0 years, range 5.0–88.7) were included (Table 1). The sample was evenly distributed by sex (52% female). Most were non-Hispanic White (62.6%). The majority of patients (55.1%) reportedly started CIC when younger than age 3 years of age. Additional demographic and condition-specific data are provided in Table 1. Distribution of bladder continence status by age at last visit and use of CIC is provided in Table 2. Only 0.6% (n = 2) of those who never started CIC were continent, ranging from none to 1.49% across three age groups, whereas continence ranged from 28.52 to 42.73% of patients across age groups at last visit.

#### Association between urinary continence and age of starting CIC

Excluding those who never started CIC, univariate logistic regression revealed that being continent of urine at the last visit was associated with age at visit, sex, race/ethnicity, highest level of education achieved, insurance type, and current bladder management strategies (Table 3). Odds of being continent at the most recent visit did not vary significantly based on age at which CIC was started.

Multivariable analyses were conducted controlling for all variables except for education and hydronephrosis degree (Table 3). The education variable was highly correlated with age at last visit and was not included in the multivariable model. Hydronephrosis degree was not included in the multivariable model due to significant amount of missing data (Table 1). After controlling for demographic, condition specific, and other intervention variables, urine continence was not significantly associated with age when CIC was started (Table 3). Compared with those who started CIC at 12 years or older, the adjusted odds ratios of being continent were 1.04 for those who initiated CIC 6–11 years of age (95% CI, 0.72 to 1.52), 1.05 for those who initiated CIC 3–5 year old (95% CI, 0.73 to 1.52), and 1.25 for those who started CIC younger than 3 (95% CI, 0.89 to 1.76).

Because initiation of CIC at a young age may be explicitly due to bladder structural and functional characteristics that may impact later continence, multivariable secondary

analysis was conducted comparing those who never started CIC to those who had, excluding participants who started CIC before age 3. Results again show that starting CIC earlier is not significantly associated with greater odds of achieving bladder continence (Table 4). Further, because certain urologic surgeries likely positively impact continence, a subsample 957 patients who never had any urology surgery were analyzed. The "never started CIC" group still had an extremely low continence rate (1.4%) compared with those who started CIC (34.8%). Multivariable logistic regression model showed similar results as the entire study sample. Finally, we examined the subset of 380 patients who had history of urologic surgery and also had appropriate data (i.e., >5 years of age, met definition of bladder impairment, information in dataset Version 2) on continence and CIC usage prior to their urologic surgery, and the finding is consistent with our entire sample (see Appendix II).

# Discussion

In individuals with myelomeningocele, starting CIC is often the first step of a program to address urinary continence. We hypothesized that earlier CIC initiation might lead to improved continence. If this hypothesis were true, a relatively simple intervention could decrease the prevalence of urinary incontinence. Continence rates differed markedly based on whether one never started CIC (0.6% of patients were continent) or started CIC at some age (ranging from 35.3 to 38.5% across age groups of starting CIC). While there was a trend toward higher odds of being continent the younger one started CIC, findings did not support the hypothesis that earlier CIC initiation is associated with a higher likelihood of urinary continence.

Guidelines on the age at which to initiate CIC in the SB population are largely driven by concerns for renal preservation. The European Association of Urology (EAU) and European Society for Pediatric Urology (ESPU) recently published joint guidelines stating that CIC should be started as soon as possible after birth [22]. The rationale for this recommendation is to decrease both renal complications and need for later augmentation. In one of the primary studies on which this recommendation is based, treatment was tailored individually over time, and some children were able to stop CIC [9]. The joint guidelines did not offer specific recommendations on when to start CIC again for continence. The International Children's Continence Society (ICCS) recommends starting CIC at birth if the child cannot empty the bladder spontaneously, with further need for CIC determined at 2-3 months of age with urodynamic and imaging parameters associated with renal deterioration [23]. As with the joint EAU-ESPU guidelines, the ICCS does not have any specific guidelines on when to start CIC for continence. In the United States, the Spina Bifida Association's Guidelines for the Care of People with Spina Bifida recommend introducing the concept of urinary continence and discussing interest in starting a continence program from 3 years of age onward [24]. This recommendation does not include a specific age for starting CIC in the absence of renal concerns.

Renal indications for starting CIC can occur throughout the lifespan. For continence, one might expect a peak of individuals starting at 3–5 years of age as a part of school readiness preparation with same age non-Spina Bifida peers having completed toilet training. In reality, children continue to start CIC at older ages. In a survey of SB patients/parents in

Turkey, Germany and the Netherlands, 22.4% started CIC at 5 years or older [25]. Our study showed 20% of those who started CIC were 6 years or older.

Even in the absence of improved continence outcomes, early initiation of CIC may offer benefits. Starting CIC is often only the first step in a continence program that may ultimately require medication and surgical intervention. Further, urinary incontinence has been shown to be negatively associated with health-related quality of life (HRQOL) in children as young as 10 years old and this negative association strengthens with increasing age [26]. Additionally, a small Swedish study demonstrated better continence and enhanced social participation in older adolescents with myelomeningocele who self-catheterized compared to an adult cohort who did not participate in a neurogenic bladder program [27].

Earlier initiation of CIC may promote timely independence with toileting skills among those with SB. Two studies with large pediatric samples assessed transition to independence with CIC [28,29]. The mean ages of transition to independent CIC were similar between the studies at 9.45 and 9.7 years of age. Atchley et al. demonstrated that 13% were capable of independent CIC by 5 years of age [29]. Unanswered is the question of whether earlier CIC initiation promotes better independence and adherence to catheterization recommendations.

Contrary to potential benefits of initiating CIC at earlier ages, there is evidence that doing so has some risks. Although CIC increases the risk of bacteriuria, many individuals rarely or never have symptomatic UTIs. However, others have recurrent symptomatic UTIs with significant morbidity. The incidence of outpatient catheter associated UTI (CAUTI) was studied at five pediatric tertiary care academic medical centers in New York City [30]. In the study, 95% of the ambulatory urinary catheter days occurred in children on CIC. Of the outpatient CAUTIs identified, 30-day outcomes included ED visits in 40% of those cases, hospital admissions in 45%, and ICU admissions in 5%. In a study including infants to adults (ages 8 months to 58 years) with SB or tethered cord who performed CIC, Chaudhry et al. found that 25% of the sample experienced frequent UTIs; increasing age was protective against recurrent UTI suggesting caution with starting CIC at younger ages [31]. Other potential complications include urethral trauma and socioeconomic costs (e.g., catheter costs, finding appropriate caregivers who can be trained to catheterize). Consequently, patients, families, and providers must balance potential benefits and risks and individualize the optimal age for starting CIC as part of a continence program.

This study has several limitations. The registry does not allow for determining an indication for starting CIC or receiving bladder surgery. In secondary analyses, we excluded individuals who started CIC prior to 3 years of age because those individuals were not likely to have started CIC as part of a continence program. However, even among individuals who started CIC after 3 years of age, some may have initiated CIC as part of a continence program while others may have started because of renal deterioration risk. Similarly, data are not available on the indication or bladder surgery. While selected bladder surgeries, such as bladder augmentation or Botulinum Toxin, chemodenervation injection, theoretically may affect continence, we cannot assert that each occurred specifically to improve this outcome. If the ratio of these indications was not constant across the different age groups for initiating CIC, true differences in continence outcomes may have been more difficult to observe.

Lower urinary tract characteristics vary widely in individuals with myelomeningocele. Accordingly, the degree of intervention required to achieve continence also varies. For CIC to help achieve urinary continence, the bladder must be able to fill with low pressures and the bladder outlet must have sufficient resistance. Urinary continence is most difficult to achieve in an individual whose bladder neck is incompetent. Even at an experienced center, only 75–81% were able to achieve a 4-h dry interval after bladder neck reconstruction [32]. The NSBPR has not been able to categorize the heterogeneity of lower urinary tract characteristics well. Urodynamic parameters were previously collected by chart review from each site; however, concerns about data quality limit the use of these data. In this study, hydronephrosis is the only variable assessed to evaluate differences in anatomy among the groups. It is a yet unanswered question whether earlier initiation of CIC could potentially improve long term bladder compliance and detrusor overactivity and lead to better continence outcomes.

There are other study limitations beyond the absence of reason for starting CIC and urodynamic data. Importantly, while the NSBPR uses a standardized definition for the variable of "Age at which CIC was started", patient/caregiver interpretation of the meaning of that item cannot be ascertained. Given that some patients with myelomeningocele may initiate and discontinue CIC over the course of the lifespan, it is possible that participants did not appreciate that this item was prompting for the age of starting long-term use. Also, in adult patients, initiation of CIC may have occurred decades prior and retrospective recall of CIC start date may be incorrect. As an additional limitation, NSBPR participation does not require clinics to ascribe to any particular intervention practices, but rather document current interventions and outcomes. As a result, considerable variability across sites regarding indications for starting CIC, particularly for continence, is likely. As a related issue, registry sites were given guidance on preferred methods of gathering information (interview, medical record review), but methods were not mandated; thus, data ascertainment method variation may impact results. Finally, study data were contributed by a group of primarily academic medical centers with clinics providing a range of multidisciplinary services. This may or may not impact access and adherence to CIC and may not be universally representative of SB care.

### Conclusions

Although CIC may be positively associated with achieving urinary continence in individuals with myelomeningocele, our study could not demonstrate that younger age at CIC initiation increased the likelihood of achieving this goal. Given continued difficulties with urinary incontinence for many with myelomeningocele despite improvements in medical and surgical interventions, continued study is warranted, particularly as it relates to age of CIC initiation and continence outcomes. Analysis of data on bladder continence gathered via the NSBPR offers a unique opportunity to improve upon methods of previous research (e.g., standardized definition of continence, data from multiple clinical sites contributing to both a larger sample and potentially greater patient representation, ability to consider correlates to continence). However, as the NSBPR is a registry documenting existing care and outcomes over time, analysis is limited to data available. Prospective studies, such as the CDC-funded Urologic Management to Preserve Initial Renal Function Protocol for Young Children with

Spina Bifida [33], are warranted to determine the impact of age at initiation of CIC on urinary continence.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

# Funding

Supported by the National Center on Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention [grants numbers DD000381, DD000382, DD000383, DD000385, DD000386, DD000387, DD000388, DD000389, DD000390, DD000736, DD000737, DD000738, DD000740, DD000742, DD000743, DD000744, DD000745, DD000766, DD000767, DD000768, DD000769, DD000770, DD000771, DD000772, DD000773, DD000774, DD001057, DD001062, DD001063, DD001065, DD001069, DD001071, DD001072, DD001073, DD001074, DD001078, DD001080, DD001082, DD001091 and DD001093].

# References

- [1]. Sandler AD. Children with spina bifida: key clinical issues. Ped Clin North Am 2010;57:879–92.
- [2]. Freeman KA, Castillo H, Castillo J, Liu T, Schechter M, Wiener JS, et al. Variation in bowel and bladder continence across US spina bifida programs: a descriptive study. J Pediatr Rehabil Med 2017;10:231–41. [PubMed: 29125511]
- [3]. Sawin KJ, Liu T, Ward E, Thibadeau J, Schechter MS, Soe MM, et al. The National Spina Bifida Registry: profile of a large cohort of participants from the first 10 clinics. J Pediatr 2015;166:444–50. [PubMed: 25444012]
- [4]. Lemelle JL, Guillemin F, Aubert D, Guys JM, Lottmann H, Lortat-Jacob S, et al. A multicenter evaluation of urinary incontinence management and outcome in spina bifida. J Urol 2006;175:208–12. [PubMed: 16406913]
- [5]. Lloyd JC, Nseyo U, Madden-Fuentes RJ, Ross SS, Wiener JS, Routh JC, et al. Reviewing definitions of urinary continence in the contemporary spina bifida literature: a call for clarity. J Pediatr Urol 2013;9:567–74. [PubMed: 23507290]
- [6]. Verhoef M, Lurvink M, Barf HA, Post MWM, van Asbeck FWA, Goosken RHJM, et al. High prevalence of incontinence among young adults with spina bifida: description, prediction and problem perception. Spin Cord 2005;43:331–40.
- [7]. Schechter MS, Liu T, Soe M, Swanson M, Ward E, Thibadeau J. Sociodemographic attributes and spina bifida outcomes. An Pediatr 2015;135(4):e957–64.
- [8]. Costa Montiero LM, Cruz GO, Fontes JM, Vieira ETRC, Santos EN, Araújo GF, et al. Early treatment improves urodynamic prognosis in neurogenic voiding dysfunction: 20 years of experience. J Pediatr 2017;93:420–7.
- [9]. Dik P, Klijn AJ, van Gool JD, de Jong-de Vos van Steenwijk CCE, de Jong TPVM. Early start to therapy preserves kidney function in spina bifida patients. J Eur Urol 2006;49:908–13.
- [10]. Elzeneini W, Waly R, Marshall D, Bailie A. Early start of clean intermittent catheterization versus expectant management in children with spina bifida. J Pediatr Surg 2019;54:322–5. [PubMed: 30558962]
- [11]. Kochakarn W, Ratana-Olarn K, Lertsithichai P, Roongreungsilp U. Follow-up of long-term treatment with clean intermittent catheterization for neurogenic bladder in children. Asian J Surg 2004;27:134–6. [PubMed: 15140666]
- [12]. Lie HR, Lagergren J, Rasumssen F, Lagerkvist B, Hagelsteen J, Börjenson MC, et al. Bowel and bladder control of children with myelomeningocele: a Nordic study. Dev Med Child Neur 1991;33:1053–61.
- [13]. Yamamoto M, Yasukawa M, Yoshii M, Takahashi S, Natsume O, Momose H, et al. Clean intermittent catheterization in the management of spina bifida: a review of 113 cases. Acta Urol Jap 1991;37:117–21 (accessed English abstract only).

- [14]. Knoll M, Madersbacher M. The chances of a spina bifida patient becoming continent/socially dry by conservative therapy. Paraplegia 1993;31:22–7. [PubMed: 8446444]
- [15]. Bille B, Ericksson B, Gierup J. Early bladder training in patients with spina bifida. Acta Paediatr Scand 1984;73:60–4. [PubMed: 6702451]
- [16]. Thibadeau JK, Ward EA, Soe MM, Liu T, Swanson M, Sawin KJ, et al. Testing the feasibility of a national spina bifida registry. Birth Defects Res A Clin Mol Teratol 2013;97:36–41. [PubMed: 23125114]
- [17]. Smith KA, Liu T, Freeman KA, Betz C, Clayton GH, Castillo H, et al. Differences in continence rates in individuals with spina bifida based on ethnicity. J Pediatr Rehabil Med 2019;12:361–8.
   [PubMed: 31744028]
- [18]. Hoffer MM, Feiwell E, Perry R, Perry J, Bonnett C. Functional ambulation in patients with myelomeningocele. J Bon Joint Surg Am 1973;55:137–48.
- [19]. Liu T, Thibadeau J, Wiener JS, Routh JC, Castillo H, Castillo J, et al. Longitudinal study of bladder continence in patients with spina bifida in the National Spina Bifida Patient Registry. J Urol 2018;199:837–42. [PubMed: 29132982]
- [20]. Weiner JS, Suson KD, Castillo J, Routh JC, Tanaka ST, Liu T, et al. Bladder management and continence outcomes in adults with spina bifida: results from the national spina bifida patient registry, 2009 to 2015. J Urol 2018;200:187–93. [PubMed: 29588216]
- [21]. Joseph DB, Baum MA, Tanaka ST, Frimberger DC, Misseri R, Khavari R, et al. Urologic guidelines for the care and management of people with spina bifida. J Pediatr Rehabil Med 2020;13:479–89. [PubMed: 33252091]
- [22]. Stein R, Bogaert G, Dogan HS, Hoen L, Kocvara R, Nijman RJM, et al. EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescents part I diagnostics and conservative treatment. Neurourol Urodyn 2020;39:45–7. [PubMed: 31724222]
- [23]. Bauer SB, Austin PF, Rawashdeh YF, de Jong TP, Franco I, Siggard C, et al. International Children's Continence Society's recommendations for initial diagnostic evaluation and followup in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn 2012;31:610–4. [PubMed: 22532312]
- [24]. Spina Bifida Association. Guidelines for the care of people with spina bifida. 2018. Accessed on 1/15/2021, http://www.spinabifidaassociation.org/guidelines/.
- [25]. Dogan HS, Stein R, 't Hoen LA, Bogaert G, Nijman RJM, Tekgul S, et al. Are EAU/ESPU pediatric urology guideline recommendations on neurogenic bladder well received by the patients? Results of a survey on awareness in spina bifida patients and caregivers. Neurourol Urodyn 2019;38:1625–31. [PubMed: 31102557]
- [26]. Szymanski KM, Cain MP, Whittam B, Kaefer M, Rink RC, Misseri R. Incontinence affects health-related quality of life in children and adolescents with spina bifida. J Pediatr Urol 2018;14:279.e1–8.
- [27]. Vu Minh Arnell M, Abrahamsson K. Urinary continence appears to enhance social participation and intimate relations in adolescents with myelomeningocele. J Pediatr Urol 2019;15:33.e1–6.
- [28]. Castillo J, Ostermaier KK, Fremion E, Collier T, Zhu H, Huang GO, et al. Urologic selfmanagement through intermittent self-catheterization among individuals with spina bifida: a journey to self-efficacy and autonomy. J Pediatr Rehabil Med 2017;10:219–26. [PubMed: 29125508]
- [29]. Atchley TJ, Dangle PP, Hopson BD, Graham A, Arynchyna AA, Rocque BG, et al. Age and factors associated with self-clean intermittent catheterization in patients with spina bifida. J Pediatr Rehabil Med 2018;11:283–91. [PubMed: 30507589]
- [30]. Rinke ML, Oyeku SO, Heo M, Saiman L, Zachariah P, Rosenberg RE, et al. Pediatric ambulatory catheter-associated urinary tract infections (CAUTIs): incidence, risk factors, and patient outcomes. Infect Control Hosp Epidemiol 2020;5:891–9.
- [31]. Chaudhry R, Balsara ZR, Madden-Fuentes RJ, Wiener JS, Routh JC, Seed P, et al. Risk factors associated with recurrent urinary tract infection n neurogenic bladders managed by clean intermittent catheterization. Urology 2017;102:213–8. [PubMed: 28065810]

- [32]. Szymanski KM, Rink RC, Whittam B, Ring JD, Misseri R, Kaefer M, et al. Long-term outcomes of the Kropp and Salle urethral lengthening bladder neck reconstruction procedures. J Pediatr Urol 2016;12:403.e1–7.
- [33]. Routh JC, Cheng EY, Austin JC, Baum MA, Gargollo PC, Grady RW, et al. Design and methodological considerations of the centers for disease control and prevention urologic and renal Protocol for the newborn and young child with spina bifida. J Urol 2016;196:1728–34. [PubMed: 27475969]

# Table 1

Distribution of key demographic and clinical characteristics of myelomeningocele patients aged 5+ years with bladder impairment according to age of initial CIC in the National Spina Bifida Patient Registry, 2013-2018.

Freeman et al.

		N (%) DY a	N (%) by age (years) CIC began	gan			
Variables	Overall n (%) (N = 3510)	Never (n = 324)	Younger than 3 (n = 1937)	3 to 5 (n = 612)	6  to  11 (n = 455)	12 and older $(n = 182)$	P-value
Age (years) group							
5 to <12	1321 (37.6)	178 (54.9)	808 (41.7)	237 (38.7)	98 (21.5)		
12 to <20	1221 (34.8)	79 (24.4)	635 (32.8)	216 (35.3)	227 (49.9)	64 (35.2)	
20 or older	968 (27.6)	67 (20.7)	494 (25.5)	159 (26.0)	130 (28.6)	118 (64.8)	<0.0001
Sex							
Male	1686~(48.0)	190 (58.6)	842 (43.5)	313 (51.1)	240 (52.7)	101 (55.5)	
Female	1824 (52.0)	134 (41.4)	1095 (56.5)	299 (48.9)	215 (47.3)	81 (44.5)	<0.0001
Race/Ethnicity (N = 3497)							
Non-Hispanic White	2189 (62.6)	177 (55.3)	1285 (66.5)	376 (61.6)	241 (53.1)	110 (60.4)	
Non-Hispanic Black	296 (8.5)	58 (18.1)	101 (5.2)	54 (8.9)	52 (11.5)	31 (17.0)	
Hispanic or Latino	790 (22.6)	59 (18.4)	452 (23.4)	125 (20.5)	118 (26.0)	36 (19.8)	
Other	222 (6.3)	26 (8.1)	93 (4.8)	55 (9.0)	43 (9.5)	5 (2.7)	<0.0001
Education $(N = 3441)$							
Elementary and below	1239 (36.0)	173 (55.3)	758 (39.9)	219 (36.1)	88 (19.9)	1(0.6)	
Middle school	480 (13.9)	36 (11.5)	269 (14.2)	87 (14.3)	83 (18.7)	5 (2.8)	
High school	1188 (34.5)	70 (22.4)	610 (32.1)	196 (32.3)	201 (45.4)	111 (62.4)	
Advanced post high school	534 (15.5)	34 (10.9)	263 (13.8)	105 (17.3)	71 (16.0)	61 (34.3)	<0.0001
Level of lesion							
Thoracic	700 (19.9)	54 (16.7)	392 (20.2)	108 (17.6)	93 (20.4)	53 (29.1)	
High-Lumbar	399 (11.4)	33 (10.2)	233 (12.0)	65 (10.6)	48 (10.5)	20 (11.0)	
Mid-Lumbar	1187 (33.8)	98 (30.2)	678 (35.0)	215 (35.1)	148 (32.5)	48 (26.4)	
Low-Lumbar	554 (15.8)	53 (16.4)	313 (16.2)	94 (15.4)	70 (15.4)	24 (13.2)	
Sacral	670 (19.1)	86 (26.5)	321 (16.6)	130 (21.2)	96 (21.1)	37 (20.3)	0.0015
Health insurance							
Any private	1574 (44.8)	128 (39.5)	901 (46.5)	280 (45.8)	196 (43.1)	69 (37.9)	
Non-private	1936 (55.2)	196 (60.5)	1036 (53.5)	332 (54.2)	259 (56.9)	113 (62.1)	0.0367

WariablesOverall n (%) (n = 3510)Neverall n (%) (n = 3510)Neverall n (%) (n = 3510)Neverall n (%) (n = 1351)Neverall n (%) (n = 1551)Peradiade (n = 1552)Peradiade (n = 152)Peradiade (n = 120)Peradiade (n = 120)Peradiade <br< th=""><th>ss         Overall n (%) (n = 3510)         Never (n = 1324)         Younger than 3 (n = 1612)         3 to 5 (n = 455)         6 to 11 (n = 455)         12 and older (n = 455)           t)ladder management (N = 3510)         (n = 1324)         3 (1.9)         13(2.1)         6(1.3)         7 (3.9)           y         869 (24.8)         178 (55.1)         36 (1.9)         13(2.1)         6(1.3)         7 (3.9)           y         869 (24.8)         178 (55.1)         36 (1.9)         132 (6.3)         84 (46.4)           y         869 (24.8)         173 (6.8)         285 (6.2)         81 (44.8)           322 (9.2)         145 (44.9)         132 (6.8)         285 (6.2)         81 (44.8)           or         1194 (34.0)         206 (67.0)         24 (3.9)         81 (44.8)           or         322 (9.9)         132 (6.8)         285 (6.2)         81 (44.8)           or         1194 (34.0)         210 (65.0)         386 (64.7)         26 (3.9)         112 (61.5)           or         2316 (66.0)         322 (99.4)         1201 (62.0)         386 (64.7)         26 (3.8)         26 (3.8)           or         1194 (34.0)         236 (3.9)         236 (3.9)         236 (3.7)         236 (3.6)         112 (6.6)         26 (3.9)</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></br<>	ss         Overall n (%) (n = 3510)         Never (n = 1324)         Younger than 3 (n = 1612)         3 to 5 (n = 455)         6 to 11 (n = 455)         12 and older (n = 455)           t)ladder management (N = 3510)         (n = 1324)         3 (1.9)         13(2.1)         6(1.3)         7 (3.9)           y         869 (24.8)         178 (55.1)         36 (1.9)         13(2.1)         6(1.3)         7 (3.9)           y         869 (24.8)         178 (55.1)         36 (1.9)         132 (6.3)         84 (46.4)           y         869 (24.8)         173 (6.8)         285 (6.2)         81 (44.8)           322 (9.2)         145 (44.9)         132 (6.8)         285 (6.2)         81 (44.8)           or         1194 (34.0)         206 (67.0)         24 (3.9)         81 (44.8)           or         322 (9.9)         132 (6.8)         285 (6.2)         81 (44.8)           or         1194 (34.0)         210 (65.0)         386 (64.7)         26 (3.9)         112 (61.5)           or         2316 (66.0)         322 (99.4)         1201 (62.0)         386 (64.7)         26 (3.8)         26 (3.8)           or         1194 (34.0)         236 (3.9)         236 (3.9)         236 (3.7)         236 (3.6)         112 (6.6)         26 (3.9)								
Niadder management (N = 3501) $36(1.9)$ $13(2.1)$ $6(1.3)$ $7(3.9)$ $240$ ( $6.9$ ) $178$ ( $55.1$ ) $36(1.9)$ $13(2.1)$ $6(1.3)$ $7(3.9)$ $x^{a}$ $869$ ( $24.8$ ) $869$ ( $24.8$ ) $869$ ( $24.8$ ) $84$ ( $46.4$ ) $x^{a}$ $2070$ ( $59.1$ ) $1296$ ( $67.0$ ) $408$ ( $66.8$ ) $287$ ( $62.9$ ) $81(46.4)$ $x^{a}$ $2070$ ( $59.1$ ) $125$ ( $44.9$ ) $132$ ( $6.8$ ) $24$ ( $3.9$ ) $12$ ( $3.6$ ) $x^{a}$ $2070$ ( $59.1$ ) $145$ ( $44.9$ ) $132$ ( $6.8$ ) $287$ ( $62.9$ ) $81$ ( $46.4$ ) $x^{a}$ $2070$ ( $59.1$ ) $2(0.6)$ $736$ ( $83.0$ ) $216$ ( $62.0$ ) $96$ ( $64.7$ ) $287$ ( $62.6$ ) $112$ ( $12.6$ ) $9(5.0)$ of urology surgery $57$ ( $27.3$ ) $138$ ( $42.6$ ) $336$ ( $64.7$ ) $287$ ( $62.6$ ) $112$ ( $61.5$ )           of urology surgery $577$ ( $29.7$ $186$ ( $57.4$ ) $146$ ( $72.9$ ) $341$ ( $72.6$ ) $126$ ( $69.2$ )           of urology surgery $577$ ( $89.9$ $146$ ( $77.0$ ) $241$ ( $72.9$ ) $246$ ( $87.6$ ) $126$ (		Variables	Overall n (%) (N = 3510)	Never (n = 324)	Younger than 3 (n = 1937)	3  to  5 (n = 612)	6  to  11 (n = 455)	12 and older (n = 182)	P-value
y240 (6.9)178 (55.1)36 (1.9)13(2.1)6(1.3)7(3.9)x869 (24.8)469 (24.3)166 (27.2)150 (33.1)84 (46.4)x2070 (59.1)1296 (67.0)408 (66.8)285 (62.9)81 (44.8)322 c (9.2)145 (44.9)132 (6.8)24 (3.9)12 (2.6)9 (5.0)continence1194 (34.0)2 (0.6)736 (38.0)216 (35.3)12 (2.6)9 (5.0)continence1194 (34.0)2 (0.6)736 (38.0)216 (35.3)170 (37.4)70 (38.5)continence1194 (34.0)2 (0.6)32 (9.94)1201 (62.0)396 (64.7)285 (62.6)112 (61.5)continence1194 (34.0)32 (99.4)1201 (62.0)396 (64.7)285 (62.6)112 (61.5)contology surgery32 (99.4)1201 (62.0)396 (64.7)285 (62.6)112 (61.5)contology surgery32 (99.4)1201 (62.0)396 (64.7)285 (62.6)112 (61.5)contology surgery32 (99.4)1201 (62.0)396 (64.7)285 (62.6)112 (61.5)contology surgery33 (42.6)485 (25.0)166 (27.1)112 (24.6)56 (30.8)contology surgery35 (42.6)138 (42.6)485 (55.6)146 (72.9)341 (72.9)56 (30.8)contology surgery33 (10.5)23 (80.9)149 (85.6)446 (72.9)341 (83.6)216 (83.8)contology surgery257 (89.9)149 (85.6)446 (72.9)341 (83.6)126 (69.2)contology surgery2679 (85.9)26		Current bladder management	t (N = 3501)						
$\chi^a$ 869 (24.8)469 (24.3)166 (27.2)150 (33.1)84 (46.4) $\chi^a$ 2070 (59.1)1296 (67.0)408 (66.8)285 (62.9)81 (44.8) $\chi^a$ 322° (9.2)145 (44.9)132 (6.8)285 (62.9)81 (44.8) $322^c (9.2)$ 145 (44.9)132 (6.8)285 (62.9)81 (44.8) $322^c (9.2)$ 145 (44.9)132 (6.8)24 (3.9)12 (2.6)9 (5.0)continence1194 (34.0)2 (0.6)736 (38.0)216 (5.3)12 (2.6)9 (5.0) $1194 (34.0)$ 2 (0.6)322 (99.4)1201 (62.0)396 (64.7)285 (62.6)112 (61.5)of urology surgery321 (96.0)322 (99.4)1201 (62.0)396 (64.7)285 (62.6)112 (61.5)of urology surgery957 (27.3)138 (42.6)485 (25.0)166 (27.1)112 (24.6)56 (30.8)of urology surgery957 (27.3)186 (57.4)1452 (75.0)446 (72.9)343 (75.4)126 (69.2)cent degree of kidney hydronephrosis (N = 3120)186 (57.4)1452 (75.0)446 (72.9)343 (75.4)126 (69.2) $201-2)$ 328 (10.5)237 (89.9)195 (11.2)44 (84.4)49 (12.0)17 (11.0) $v(1-2)$ 328 (10.5)3 (1.0)40 (2.3)17 (3.2)6 (3.9) $v(2,2)$ 78 (2.5)3 (1.0)40 (2.3)17 (3.2)6 (3.9) $v(1-2)$ 78 (1.0)3 (1.0)17 (1.0)7 (1.3)6 (1.5)2 (1.9) $v(2,2)$ 3 (1.0)3 (1.0)17 (1.0)7 (1.3)17		None	240 (6.9)	178 (55.1)	36 (1.9)	13(2.1)	6(1.3)	7 (3.9)	
$x^a$ $2070(59.1)$ $1296(67.0)$ $408(66.8)$ $285(62.9)$ $81(44.8)$ $322^c(9.2)$ $145(44.9)$ $132(6.8)$ $24(3.9)$ $12(2.6)$ $9(5.0)$ continence $1194(34.0)$ $2(0.6)$ $736(38.0)$ $216(35.3)$ $170(37.4)$ $70(38.5)$ continence $1194(34.0)$ $2(0.6)$ $736(38.0)$ $216(66.1)$ $322(99.4)$ $1201(62.0)$ $396(64.7)$ $285(62.6)$ $112(61.5)$ of urology surgery $322(27.3)$ $322(99.4)$ $1201(62.0)$ $396(64.7)$ $285(62.6)$ $112(61.5)$ of urology surgery $3216(66.0)$ $322(99.4)$ $1201(62.0)$ $396(64.7)$ $285(62.6)$ $112(61.5)$ of urology surgery $327(27)$ $322(99.4)$ $1201(62.0)$ $396(64.7)$ $285(62.6)$ $112(61.5)$ of urology surgery $327(27.3)$ $138(42.6)$ $485(25.0)$ $166(27.1)$ $112(2.6)$ $56(30.8)$ of urology surgery $257(27.3)$ $186(57.4)$ $146(72.9)$ $341(83.6)$ $126(69.2)$ cent de		CIC only	869 (24.8)		469 (24.3)	166 (27.2)	150 (33.1)	84 (46.4)	
322 $^{c}(9.2)$ 145 (44.9)132 (6.8)24 (3.9)12 (2.6)9 (5.0)continence1194 (34.0)2 (0.6)736 (38.0)216 (35.3)170 (37.4)70 (38.5) $2316 (66.0)$ 322 (99.4)1201 (62.0)396 (64.7)285 (62.6)112 (61.5)of urology surgery957 (27.3)138 (42.6)485 (25.0)166 (27.1)112 (24.6)56 (30.8)cont degree of kidney hydronephrosis (N = 3120)cont degree of kidney hydronephrosis (N = 3120)3 (10.5)257 (89.9)1496 (85.6)341 (83.6)129 (83.8)colspan="4">cont degree of kidney hydronephrosis (N = 3120)cont degree of kidney hydronephrosis (N = 3120)cont degree of kidney hydrone phrosis (N = 3120)cont degree (SFU 3)<		$CIC + Rx^{2}$	2070 (59.1)		1296 (67.0)	408 (66.8)	285 (62.9)	81 (44.8)	
2 (0.6)       736 (38.0)       216 (35.3)       170 (37.4)       70 (38.5)         322 (99.4)       1201 (62.0)       396 (64.7)       285 (62.6)       112 (61.5)         138 (42.6)       485 (25.0)       166 (27.1)       112 (24.6)       56 (30.8)         138 (42.6)       485 (25.0)       166 (27.1)       112 (24.6)       56 (30.8)         186 (57.4)       1452 (75.0)       446 (72.9)       343 (75.4)       126 (69.2)         257 (89.9)       1496 (85.6)       456 (87.0)       341 (83.6)       126 (69.2)         26 (87.0)       195 (11.2)       44 (8.4)       49 (12.0)       17 (11.0)         3 (1.0)       40 (2.3)       17 (3.2)       12 (2.9)       6 (3.9)         3 (1.0)       17 (1.0)       7 (1.3)       6 (1.5)       2 (1.3)		Otherb	322 <sup>c</sup> (9.2)	145 (44.9)	132 (6.8)	24 (3.9)	12 (2.6)	9 (5.0)	<0.0001
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Bladder continence							
322 (99.4)       1201 (62.0)       396 (64.7)       285 (62.6)       112 (61.5)         138 (42.6)       485 (25.0)       166 (27.1)       112 (24.6)       56 (30.8)         186 (57.4)       1452 (75.0)       166 (27.1)       112 (24.6)       56 (30.8)         186 (57.4)       1452 (75.0)       446 (72.9)       343 (75.4)       126 (69.2)         257 (89.9)       1496 (85.6)       456 (87.0)       341 (83.6)       129 (83.8)         257 (89.9)       1996 (85.6)       456 (87.0)       341 (83.6)       129 (83.8)         26 (30.0)       195 (11.2)       44 (8.4)       49 (12.0)       17 (11.0)         3 (1.0)       40 (2.3)       17 (3.2)       12 (2.9)       6 (3.9)         3 (1.0)       17 (1.0)       7 (1.3)       6 (1.5)       2 (1.3)		Yes	1194 (34.0)	2 (0.6)	736 (38.0)	216 (35.3)	170 (37.4)	70 (38.5)	
138 (42.6)       485 (25.0)       166 (27.1)       112 (24.6)       56 (30.8)         186 (57.4)       1452 (75.0)       446 (72.9)       343 (75.4)       126 (69.2)         257 (89.9)       1496 (85.6)       456 (87.0)       341 (83.6)       126 (69.2)         23 (8.0)       195 (11.2)       44 (8.4)       49 (12.0)       17 (11.0)         3 (1.0)       40 (2.3)       17 (3.2)       12 (2.9)       6 (3.9)         3 (1.0)       17 (1.0)       7 (1.3)       6 (1.5)       2 (1.3)		No	2316 (66.0)	322 (99.4)	1201 (62.0)	396 (64.7)	285 (62.6)	112 (61.5)	<0.0001
138 (42.6)         485 (25.0)         166 (27.1)         112 (24.6)         56 (30.8)           186 (57.4)         1452 (75.0)         446 (72.9)         343 (75.4)         126 (69.2)           257 (89.9)         1496 (85.6)         456 (87.0)         341 (83.6)         126 (69.2)           257 (89.9)         1496 (85.6)         456 (87.0)         341 (83.6)         129 (83.8)           23 (8.0)         195 (11.2)         44 (8.4)         49 (12.0)         17 (11.0)           3 (1.0)         40 (2.3)         17 (3.2)         12 (2.9)         6 (3.9)           3 (1.0)         17 (1.0)         7 (1.3)         6 (1.5)         2 (1.3)		History of urology surgery							
186 (57.4)         1452 (75.0)         446 (72.9)         343 (75.4)         126 (69.2)           257 (89.9)         1496 (85.6)         456 (87.0)         341 (83.6)         129 (83.8)           23 (8.0)         195 (11.2)         44 (8.4)         49 (12.0)         17 (11.0)           3 (1.0)         40 (2.3)         17 (3.2)         12 (2.9)         6 (3.9)           3 (1.0)         17 (1.0)         7 (1.3)         6 (1.5)         2 (1.3)		No	957 (27.3)	138 (42.6)	485 (25.0)	166 (27.1)	112 (24.6)	56 (30.8)	
257 (89.9)       1496 (85.6)       456 (87.0)       341 (83.6)       129 (83.8)         23 (8.0)       195 (11.2)       44 (8.4)       49 (12.0)       17 (11.0)         3 (1.0)       40 (2.3)       17 (3.2)       12 (2.9)       6 (3.9)         3 (1.0)       17 (1.0)       7(1.3)       6(1.5)       2(1.3)		Yes	2553 (72.7)	186 (57.4)	1452 (75.0)	446 (72.9)	343 (75.4)	126 (69.2)	<0.0001
2679 (85.9)         257 (89.9)         1496 (85.6)         456 (87.0)         341 (83.6)         129 (83.8)           SFU1-2)         328 (10.5)         23 (8.0)         195 (11.2)         44 (8.4)         49 (12.0)         17 (11.0)           rate (SFU 3)         78 (2.5)         3 (1.0)         40 (2.3)         17 (3.2)         12 (2.9)         6 (3.9)           c (SFU 4)         35 (1.1)         3 (1.0)         17 (1.0)         7 (1.3)         6 (1.5)         2 (1.3)		Most recent degree of kidney l	hydronephrosis (N = 3120)						
328 (10.5)         23 (8.0)         195 (11.2)         44 (8.4)         49 (12.0)         17 (11.0)           3)         78 (2.5)         3 (1.0)         40 (2.3)         17 (3.2)         12 (2.9)         6 (3.9)           35 (1.1)         3 (1.0)         17 (1.0)         7 (1.3)         6 (1.5)         2 (1.3)		None	2679 (85.9)	257 (89.9)	1496 (85.6)	456 (87.0)	341 (83.6)	129 (83.8)	
3)         78 (2.5)         3 (1.0)         40 (2.3)         17 (3.2)         12 (2.9)         6 (3.9)           35(1.1)         3 (1.0)         17 (1.0)         7 (1.3)         6 (1.5)         2 (1.3)		Mild (SFU1–2)	328 (10.5)	23 (8.0)	195 (11.2)	44 (8.4)	49 (12.0)	17 (11.0)	
35(1.1) 3 (1.0) 17 (1.0) 7(1.3) 6(1.5) 2(1.3)		Moderate (SFU 3)	78 (2.5)	3 (1.0)	40 (2.3)	17(3.2)	12 (2.9)	6 (3.9)	
	Abbreviations: CIC = Clean Intermittent Catheterization, Rx = prescribed medication, SFU = Society of Fetal Urology grading system.	Severe (SFU 4)	35(1.1)	3 (1.0)	17 (1.0)	7(1.3)	6(1.5)	2(1.3)	0.38

J Pediatr Urol. Author manuscript; available in PMC 2023 October 01.

<sup>b</sup>Included Crede, cystectomy, indwelling catheter, spontaneous void, vesicostomy, urostomy bag, urinary diversion, Rx, and one or more of them in combination.

 $\mathcal{C}_{\rm Note}$  that only 3(0.9% ) patients in this group were continent of bladder.

Author Manuscript

Author Manuscript

Author Manuscript

Distribution of bladder continence status by age at visit and CIC usage. The National Spina Bifida Patient Registry, 2013–2018.

	Z	$N \ (\%)$ of being continent of bladder, subgroup $n$	adder, subgroup n
		Never started CIC $(n = 324)$ Started CIC $(n = 3186)$	Started CIC (n = 3186)
Age group (years)			
5 to <12	1321	1321 1 (0.56), $n = 178$	326 (28.52), n = 1143
12 to <20	1221	0 (0), n = 79	481 (42.12), n = 1142
20 or older	968	968 1 (1.49), $n = 67$	385 (42.73), n = 901

-
<u> </u>
t
5
ō
¥
$\geq$
5
la
lanu
lanu
lanu
lanu
lanuscr
lanus

# Table 3

Summary of univariate and multiple logistic regressions on bladder continence outcome. The National Spina Bifida Patient Registry, 2013–2018.<sup>a</sup>

Variables	Crude Odds Ratio (95%CI)	P-value	Adjusted Odds Ratio (95% CI) <sup>b</sup>	P-value
Age at visit		<0.0001 <i>d</i>		<0.0001 <sup>d</sup>
5 to <12 $^{C}$				
12 to <20	1.82 (1.53–2.17)	<0.0001	1.73 (1.43–2.08)	
20 or older	1.87 (1.56–2.25)	<0.0001	1.69 (1.37–2.09)	
Gender				
Male <sup>c</sup>				
Female	1.42 (1.23–1.64)	<0.0001	1.37 (1.18–1.60)	<0.0001 <i>d</i>
Race/Ethnicity		$< 0.0001^{d}$		0.0082 <sup>d</sup>
Non-Hispanic White <sup>C</sup>				
Non-Hispanic Black	0.83 (0.62–1.09)	0.1790	0.98 (0.72–1.33)	0.88
Hispanic or Latino	0.64 (0.53-0.77)	<0.0001	0.72 (0.59–0.89)	0.0017
Other	0.68 (0.49–0.92)	0.0143	0.74 (0.53–1.03)	0.0778
Education		<0.0001 <sup>d</sup>	Not Applicable	
Elementary and below $c$				
Middle school	1.34 (1.06–1.69)	0.0156		
High school	1.90 (1.59–2.28)	<0.0001		
Advanced post high school	2.11 (1.69–2.63)	<0.0001		
Level of lesion		0.24d		$0.0654^{d}$
Thoracic <sup>C</sup>				
High-Lumbar	1.31 (1.01–1.71)	0.0417	1.43 (1.08–1.90)	0.0124
Mid-Lumbar	1.02 (0.83–1.25)	0.84	1.04 (0.84–1.30)	0.71
Low-Lumbar	1.10 (0.86–1.40)	0.46	1.19 (0.91–1.54)	0.20
Sacral	1.14 (0.91–1.44)	0.26	1.23 (0.95–1.58)	0.1137
Health Insurance				
Any private $c$				
Non-private	0.66 (0.57–0.76)	<0.0001	0.69 (0.59–0.82)	<0.0001

Current bladder management (excluding nome <sup>7</sup> ) $<0.0001^d$ $<0.0001^d$ $<0.0001^d$ CIC only <sup>c</sup> CiC rls $<0.0001^d$ $<0.0001^d$ $<0.0001^d$ $<0.0001^d$ CIC + Rx $0.65 (0.55 - 0.76)$ $<0.0001$ $0.68 (0.57 - 0.80)$ $<0.000-0.05$ $<0.000-0.05$ $<0.000-0.05$ Ohber <sup>d</sup> $0.01 (0.00-0.05)$ $<0.0001$ $<0.000-0.05$ $<0.000-0.05$ $<0.000-0.05$ Age of initial CIC $0.01 (0.00-0.05)$ $<0.0001$ $<0.000-0.05$ $<0.0001$ $<0.000-0.05$ Ja ad older <sup>c</sup> $0.01 (0.00-0.05)$ $<0.0001$ $<0.0001$ $<0.000-0.05$ $<0.0000$ Ja ad older <sup>c</sup> $<0.0001$ $<0.0001$ $<0.0001$ $<0.000-0.05$ $<0.0001$ Ja ad older <sup>c</sup> $<0.0001$ $<0.0001$ $<0.0001$ $<0.0001$ $<0.00000$ Ja ad older <sup>c</sup> $<0.0001$ $<0.0001$ $<0.0001$ $<0.0001$ $<0.0001$ Ja ad older <sup>c</sup> $<0.0001$ $<0.0001$ $<0.0001$ $<0.0001$ $<0.0001$ Ja obsech $<0.0001$ $<0.0001$ <th>Variables</th> <th>Crude Odds Ratio (95%CI)</th> <th>P-value</th> <th>Adjusted Odds Ratio (95% CI)<sup>b</sup></th> <th>P-value</th>	Variables	Crude Odds Ratio (95%CI)	P-value	Adjusted Odds Ratio (95% CI) <sup>b</sup>	P-value
$y^c$ $0.65 (0.55 - 0.76)$ $< 0.0001$ $0.68 (0.57 - 0.80)$ inial CIC $0.01 (0.00 - 0.04)$ $< 0.001$ $0.01 (0.00 - 0.05)$ inial CIC $0.01 (0.00 - 0.04)$ $< 0.0001$ $0.01 (0.00 - 0.05)$ ider <sup>c</sup> $0.57d$ $< 0.67d$ $0.01 (0.00 - 0.05)$ ider <sup>c</sup> $0.57d$ $0.67d$ $0.01 (0.00 - 0.05)$ ider <sup>c</sup> $0.57d$ $0.67d$ $0.01 (0.00 - 0.05)$ ider <sup>c</sup> $0.57d$ $0.80$ $1.04 (0.72 - 1.52)$ ider <sup>c</sup> $0.90$ $0.80$ $1.04 (0.72 - 1.52)$ ider <sup>c</sup> $0.90$ $0.00$ $1.25 (0.89 - 1.76)$ of urology surgery $0.90$ $0.126 (0.73 - 1.52)$ $0.90$ $1.16 (0.97 - 1.39)$ of urology surgery $0.90$ $0.724 + 1.37$ $0.90$ $1.16 (0.97 - 1.39)$ of urology surgery $0.90$ $0.724 + 1.37$ $0.90$ $1.16 (0.97 - 1.39)$ ethrosis degree $1.16 (0.99 - 1.37)$ $0.0764$ Not Applicable         ethrosis degree $1.25 (0.98 - 1.59)$ $0.0764$ Not Applicable         ethrosis degree0.779 - 2.02 $0.35$ <th< td=""><td>Current bladder management (excluding none<math>f_j</math></td><td></td><td>&lt;0.0001<sup>d</sup></td><td></td><td>&lt; 0.0001 d</td></th<>	Current bladder management (excluding none $f_j$		<0.0001 <sup>d</sup>		< 0.0001 d
x $0.55$ ( $0.55$ - $0.76$ ) $< 0.0001$ $0.68$ ( $0.57$ - $0.80$ ) <b>initial CIC</b> $0.01$ ( $0.00$ - $0.05$ ) $< 0.001$ $0.01$ ( $0.00$ - $0.05$ ) <b>initial CIC</b> $0.67d$ $0.01$ ( $0.00$ - $0.05$ ) <b>ider</b> <sup>c</sup> $0.95$ ( $0.67$ - $1.36$ ) $0.80$ $1.04$ ( $0.72$ - $1.52$ ) <b>ider</b> <sup>c</sup> $0.95$ ( $0.67$ - $1.36$ ) $0.80$ $1.04$ ( $0.72$ - $1.52$ ) <b>ider</b> <sup>c</sup> $0.95$ ( $0.67$ - $1.36$ ) $0.80$ $1.04$ ( $0.72$ - $1.52$ ) <b>ider</b> <sup>c</sup> $0.98$ ( $0.72$ - $1.34$ ) $0.90$ $1.04$ ( $0.72$ - $1.52$ ) <b>ider</b> <sup>c</sup> $0.98$ ( $0.72$ - $1.34$ ) $0.90$ $1.04$ ( $0.72$ - $1.52$ ) <b>ider</b> <sup>c</sup> $0.98$ ( $0.72$ - $1.34$ ) $0.90$ $1.04$ ( $0.79$ - $1.39$ ) <b>ider</b> <sup>c</sup> $0.98$ ( $0.72$ - $1.34$ ) $0.90$ $1.16$ ( $0.97$ - $1.39$ ) <b>ider</b> <sup>c</sup> $0.704$ $0.90$ $1.16$ ( $0.97$ - $1.39$ ) <b>ider</b> <sup>c</sup> $0.704$ $0.90$ $0.116$ ( $0.97$ - $1.39$ ) <b>ider</b> <sup>c</sup> $0.120$ $0.126$ $0.116$ ( $0.97$ - $1.39$ ) <b>ider</b> <sup>c</sup> $0.120$ $0.126$ $0.116$ ( $0.97$ - $1.39$ ) <b>ider</b> <sup>c</sup> $0.120$ $0.076d$ Not Applicable <tr< td=""><td><math>\operatorname{CIC}\operatorname{only}^{\mathcal{C}}</math></td><td></td><td></td><td></td><td></td></tr<>	$\operatorname{CIC}\operatorname{only}^{\mathcal{C}}$				
nitial CIC $0.01 (0.00-0.04)$ $< 0.001 (0.00-0.05)$ nitial CIC $0.67d$ $0.67d$ $\mathrm{older}^{C}$ $0.95 (0.67-1.36)$ $0.80 (0.72-1.52)$ $\mathrm{older}^{C}$ $0.95 (0.67-1.36)$ $0.80 (0.72-1.52)$ $\mathrm{older}^{C}$ $0.95 (0.67-1.36)$ $0.80 (0.72-1.52)$ $\mathrm{older}^{C}$ $0.95 (0.67-1.36)$ $0.43 (0.72-1.52)$ $\mathrm{older}^{C}$ $0.98 (0.72-1.23)$ $0.43 (0.69-1.52)$ $\mathrm{older}^{C}$ $0.98 (0.72-1.34)$ $0.90 (0.72-1.52)$ $\mathrm{older}^{C}$ $0.98 (0.72-1.34)$ $0.90 (0.72-1.52)$ $\mathrm{older}^{C}$ $0.98 (0.72-1.34)$ $0.90 (0.77-1.34)$ $\mathrm{older}^{C}$ $0.98 (0.72-1.34)$ $0.90 (0.97-1.34)$ $\mathrm{older}^{C}$ $0.90 (0.72-1.34)$ $0.90 (0.97-1.34)$ $\mathrm{older}^{C}$ $0.90 (0.97-1.34)$ $0.0764$ $\mathrm{older}^{C}$ $0.0764$ $0.0764$ $\mathrm{eller}^{C}$ $0.20d$ $0.0764$ $\mathrm{eller}^{C}$ $0.99-2.02$ $0.33$ $\mathrm{eller}^{C}$ $0.35$ $0.35$	CIC + Rx	0.65 (0.55–0.76)	<0.0001	$0.68\ (0.57-0.80)$	
initial CIC $0.67d$ older <sup>c</sup> $0.67d$ $0.67-1.36$ $0.80$ $1.04$ $(0.72-1.52)$ 0.87 $(0.62-1.23)$ $0.43$ $1.05$ $(0.73-1.52)0.87$ $(0.62-1.23)$ $0.90$ $1.25$ $(0.89-1.76)of urology surgery 0.98 (0.72-1.34) 0.90 1.25 (0.89-1.76)0.0729$ $1.16$ $(0.97-1.39)hephrosis degree 0.20d 0.0729 1.16 (0.97-1.39)1.16$ $(0.99-1.37)$ $0.0729$ $1.16$ $(0.97-1.39)1.26$ $(0.99-1.59)$ $0.0764the (SFU 3) 1.26 (0.79-2.02) 0.33(SFU 4) 1.39 0.0764$	Other <sup>e</sup>	0.01 (0.00-0.04)	<0.0001	0.01 (0.00–0.05)	
older <sup>c</sup> $0.95 (0.67-1.36)  0.80  1.04 (0.72-1.52) \\ 0.87 (0.62-1.23)  0.43  1.05 (0.73-1.52) \\ 0.98 (0.72-1.34)  0.90  1.25 (0.89-1.76) \\ 0.100 \text{ of urology surgery} \\ 1.16 (0.99-1.37)  0.0729  1.16 (0.97-1.39) \\ 1.16 (0.99-1.37)  0.0729  1.16 (0.97-1.39) \\ 1.16 (0.99-1.37)  0.0764 \\ \text{FU1-2) } 1.25 (0.98-1.59)  0.0764 \\ \text{te (SFU 3) } 1.26 (0.79-2.02)  0.33 \\ (SFU 4)  1.39 (0.69-2.82)  0.35 \\ \end{array}$	Age of initial CIC		0.67 <i>d</i>		$0.1693^{d}$
$\begin{array}{llllllllllllllllllllllllllllllllllll$	12 and older $^{\mathcal{C}}$				
0.87 (0.62-1.23) $0.43$ $1.05 (0.73-1.52)$ r than 3 $0.98 (0.72-1.34)$ $0.90$ $1.25 (0.89-1.76)$ of urology surgery $1.16 (0.99-1.37)$ $0.0729$ $1.16 (0.97-1.39)$ nephrosis degree $0.20d$ $Not Applicable$ FU1-2) $1.25 (0.98-1.59)$ $0.0764$ tc (SFU 3) $1.26 (0.79-2.02)$ $0.33$ (SFU 4) $1.39 (0.69-2.82)$ $0.35$	6 to 11	0.95 (0.67–1.36)	0.80	1.04 (0.72–1.52)	0.83
r than 3 $0.98 (0.72-1.34)$ $0.90$ $1.25 (0.89-1.76)$ of urology surgery1.16 $(0.99-1.37)$ $0.0729$ $1.16 (0.97-1.39)$ nephrosis degree $0.20d$ Not ApplicableFU1-2) $1.25 (0.98-1.59)$ $0.0764$ te (SFU 3) $1.26 (0.79-2.02)$ $0.33$ (SFU 4) $1.39 (0.69-2.82)$ $0.35$	3 to 5	0.87 (0.62–1.23)	0.43	1.05 (0.73–1.52)	0.78
of urology surgery $1.16 (0.99-1.37)  0.0729  1.16 (0.97-1.39)$ rephrosis degree $0.20d  Not Applicable$ $FU1-2)  1.25 (0.98-1.59)  0.0764$ te (SFU 3) $1.26 (0.79-2.02)  0.33$ (SFU 4) $1.39 (0.69-2.82)  0.35$	Younger than 3	0.98 (0.72–1.34)	06.0	1.25 (0.89–1.76)	0.20
III6 (0.99–1.37)       0.0729       III6 (0.97–1.39)         Rephrosis degree $0.20d$ Not Applicable         FU1–2)       II25 (0.98–1.59) $0.0764$ te (SFU 3)       I.39 (0.69–2.82) $0.35$ (SFU 4)       I.39 (0.69–2.82) $0.35$	History of urology surgery				
I.16 (0.99-1.37)     0.0729     I.16 (0.97-1.39)       nephrosis degree     0.20d     Not Applicable       FU1-2)     I.25 (0.98-1.59)     0.0764       te (SFU 3)     I.26 (0.79-2.02)     0.33       (SFU 4)     I.39 (0.69-2.82)     0.35	No <sup>c</sup>				
rephrosis degree         0.20d           FU1-2)         1.25 (0.98-1.59)         0.0764           te (SFU 3)         1.26 (0.79-2.02)         0.33           (SFU 4)         1.39 (0.69-2.82)         0.35	Yes	1.16 (0.99–1.37)	0.0729	1.16 (0.97–1.39)	0.0969
.FUI-2) 1.25 (0.98-1.59) te (SFU 3) 1.26 (0.79-2.02) (SFU 4) 1.39 (0.69-2.82)	Hydronephrosis degree		$0.20^{d}$	Not Applicable	
1.25 (0.98–1.59) 1.26 (0.79–2.02) 1.39 (0.69–2.82)	None c				
1.26 (0.79–2.02) 1.39 (0.69–2.82)	Mild (SFU1–2)	1.25 (0.98–1.59)	0.0764		
1.39 (0.69–2.82)	Moderate (SFU 3)	1.26 (0.79–2.02)	0.33		
	Severe (SFU 4)	1.39 (0.69–2.82)	0.35		
	110 Trevel staticul CAC group was excluded.	the multiple regress	sion model.		
The rever started CLC group was excluded. $b_{3107}$ patients with non-missing data were included in the multiple regression model.	$^{\mathcal{C}}$ Reference group.				
The Never staticul CLC group was excluded. $b_{3107}$ patients with non-missing data were included in the multiple regression model. <sup>C</sup> Reference group.	d				

Author Manuscript

f Included Crede, cystectomy, indwelling catheter, spontaneous void, vesicostomy, urostomy bag, urinary diversion, Rx, and one or more of them in combination.

 $e^{t}$ The None management group (n – 240) was excluded since all patients in this subgroup were incontinent.

 $d_{
m Overall}$  p-value.

Author Manuscript

# Table 4

Summary of univariate (n = 1249) and multiple (n = 1216) logistic regressions on bladder continence outcome. The National Spina Bifida Patient Registry, 2013–2018 (excluded Never started CIC and CIC started <3 years groups).

Age at Visit $-0.0001^{\circ}$ $-0.0001^{\circ}$ $-0.0001^{\circ}$ $-0.0001^{\circ}$ 5 to $<12^{b}$ 5 to $<12^{b}$ $<0.0001$ $2.14 (1.53 - 2.9)$ $<0.0001$ 2 to $<200$ 0 to dee $2.35 (1.71 - 3.23)$ $<0.0001$ $2.14 (1.53 - 2.9)$ $<0.0001$ 2 to $<0.0001$ $2.35 (1.71 - 3.23)$ $<0.0001$ $2.14 (1.53 - 2.9)$ $<0.0001$ Center $Male^{b}$ $1.30 (1.03 - 1.63)$ $0.020^{\circ}$ $1.31 (1.02 - 1.67)$ $0.0011^{\circ}$ Male $Non-Hispanic White^{b}$ $1.30 (1.03 - 1.63)$ $0.0020^{\circ}$ $0.0175^{\circ}$ $0.0175^{\circ}$ Non-Hispanic White^{b} $Non-Hispanic White^{b}$ $0.74 (0.50 - 1.08)$ $0.01180$ $0.01 (0.53 - 1.23)$ $0.0174^{\circ}$ Non-Hispanic White^{b} $0.74 (0.50 - 1.08)$ $0.0180^{\circ}$ $0.0174^{\circ}$ $0.0174^{\circ}$ Non-Hispanic White^{b} $0.74 (0.50 - 1.08)$ $0.0180^{\circ}$ $0.0100^{\circ}$ $0.0180^{\circ}$ $0.0174^{\circ}$ Non-Hispanic White^{b} $0.74 (0.50 - 1.08)$ $0.0180^{\circ}$ $0.016^{\circ}$ $0.016^{\circ}$ $0.016^{\circ}$ Hispanic O		Crude Odds Ratio (95% CI)	P-value	Adjusted Odds Ratio (95% CI) <sup>d</sup>	P-value
2.22 (1.63-3.02) $<0.0001$ $2.14 (1.53-2.90)$ 2.35 (1.71-3.23) $<0.0001$ $2.14 (1.53-2.90)$ city $0.0020^{\circ}$ $2.28 (1.58-3.30)$ city $0.0020^{\circ}$ $0.0120^{\circ}$ ic White <sup>b</sup> $0.0020^{\circ}$ $0.01020^{\circ}$ ic White <sup>b</sup> $0.0020^{\circ}$ $0.01020^{\circ}$ ic Black $0.74 (0.50-1.08)$ $0.1180$ $0.81 (0.53-1.23)$ ic Black $0.74 (0.50-1.08)$ $0.1180$ $0.81 (0.53-1.23)$ Latino $0.78 (0.51-1.20)$ $0.266$ $0.93 (0.58-1.47)$ Latino $0.78 (0.51-1.20)$ $0.266$ $0.93 (0.58-1.47)$ And below <sup>b</sup> $1.15 (0.75-1.74)$ $0.26$ $0.93 (0.58-1.47)$ and below <sup>b</sup> $1.15 (0.75-1.74)$ $0.52$ $0.4001$ and below <sup>b</sup> $1.15 (0.75-1.74)$ $0.52$ $0.6001$ and below <sup>b</sup> $1.15 (0.75-1.74)$ $0.52$ $0.6001$ and below <sup>b</sup> $0.116$ $0.66^{\circ}$ $0.93 (0.58-1.47)$ and below <sup>b</sup> $0.116 (0.88-2.10)$ $0.66^{\circ}$ $0.66^{\circ}$ and below <sup>b</sup> $0.110 (0.88-2.10)$ $0.0001$	ge at visit		<0.0001 <i>c</i>		<0.0001 $c$
2.22 (1.53-3.02) $< 0.0001$ $2.14 (1.53-2.9)$ $2.35 (1.71-3.23)$ $< 0.0001$ $2.28 (1.58-3.30)$ $2.35 (1.71-3.23)$ $0.0020^{\circ}$ $1.31 (1.02-1.67)$ $\operatorname{icthy}$ $0.0020^{\circ}$ $0.0020^{\circ}$ $\operatorname{icthy}$ $0.0020^{\circ}$ $0.0020^{\circ}$ $\operatorname{icthy}$ $0.0020^{\circ}$ $0.0020^{\circ}$ $\operatorname{icthy}$ $0.0020^{\circ}$ $0.00020^{\circ}$ $\operatorname{icthy}$ $0.74 (0.50-1.08)$ $0.1180$ $\operatorname{icthy}$ $0.74 (0.50-1.08)$ $0.1180$ $\operatorname{icthy}$ $0.74 (0.50-1.08)$ $0.0002^{\circ}$ $\operatorname{icthy}$ $0.74 (0.50-1.03)$ $0.0002^{\circ}$ $\operatorname{icthy}$ $0.74 (0.50-1.03)$ $0.0002^{\circ}$ $\operatorname{icthy}$ $0.74 (0.50-1.03)$ $0.0002^{\circ}$ $\operatorname{icthy}$ $0.74 (0.50-1.03)$ $0.0001^{\circ}$ $\operatorname{icthy}$ $0.0001^{\circ}$ $0.66 (0.47-0.93)$ $\operatorname{icthy}$ $0.0001^{\circ}$ $0.66 (0.47-0.93)$ $\operatorname{icthy}$ $0.0001^{\circ}$ $0.66 (0.47-0.93)$ $\operatorname{icthy}$ $0.0001^{\circ}$ $0.66 (0.47-0.93)$ $\operatorname{icthy}$ $0.0001^{\circ}$ $0.52^{\circ}$ $\operatorname{icthy}$ $0.52^{\circ}$ $0.0001^{\circ}$ $\operatorname{icthy}$ $0.52^{\circ}$ $0.0001^{\circ}$ $\operatorname{icthy}$ $0.66^{\circ}$ $0.66^{\circ}$ $\operatorname{icthy}$ $0.66^{\circ}$ $0.66^{\circ}$ $\operatorname{icthy}$ $0.66^{\circ}$ $0.66^{\circ}$ $\operatorname{icthy}$ $0.66^{\circ}$ $0.6001^{\circ}$ $\operatorname{icthy}$ $0.52^{\circ}$ $0.0001^{\circ}$ $\operatorname{icthy}$ $0.52^{\circ}$ $0.0001^{\circ}$ $\operatorname{icthy}$ $0.52^{\circ}$ $0.0001^{\circ}$	to <12 <i>b</i>				
$2.35(1.71-3.23)$ $<0.0001$ $2.28(1.58-3.30)$ icity $1.30(1.03-1.63)$ $0.0273$ $1.31(1.02-1.67)$ icity $0.0020^c$ $0.001^c$ $0.0100^c$ ic Mhite <sup>b</sup> $0.74(0.50-1.08)$ $0.1180$ $0.81(0.53-1.23)$ ic Black $0.74(0.50-1.08)$ $0.1002$ $0.66(0.47-0.93)$ ic Black $0.78(0.51-1.20)$ $0.26$ $0.93(0.58-1.47)$ Latino $0.78(0.51-1.20)$ $0.26$ $0.93(0.58-1.47)$ Latino $0.78(0.51-1.20)$ $0.26$ $0.93(0.58-1.47)$ Jathold $0.78(0.51-1.20)$ $0.26$ $0.93(0.58-1.47)$ Latino $0.78(0.51-1.20)$ $0.26$ $0.93(0.58-1.47)$ Jathold $0.78(0.51-1.20)$ $0.26$ $0.93(0.58-1.47)$ Jathold $0.78(0.51-1.20)$ $0.26$ $0.93(0.58-1.47)$ and below <sup>b</sup> $1.15(0.75-1.74)$ $0.52$ $0.0001$ of $1.15(0.75-1.74)$ $0.52$ $0.0001$ of $0.52(1.58-3.26)$ $0.66^c$ of $0.66^c$ $0.66^c$ of $0$	2 to <20	2.22 (1.63–3.02)	<0.0001	2.14 (1.53–2.99)	<0.0001
icity $1.30(1.03-1.63)$ $0.0273$ $1.31(1.02-1.67)$ icity $0.0020c$ $1.31(1.02-1.67)$ ic Black $0.0020c$ $0.0002$ $0.06(0.47-0.93)$ Latino $0.78(0.51-1.20)$ $0.0002$ $0.66(0.47-0.93)$ Latino $0.78(0.51-1.20)$ $0.0002$ $0.66(0.47-0.93)$ Latino $0.78(0.51-1.20)$ $0.0002$ $0.66(0.47-0.93)$ Latino $0.78(0.51-1.20)$ $0.26$ $0.93(0.58-1.47)$ Ad below <sup>b</sup> $1.15(0.75-1.74)$ $0.26$ $0.93(0.58-1.47)$ and below <sup>b</sup> $1.15(0.75-1.74)$ $0.26$ $0.93(0.58-1.47)$ ol $0.0012$ $0.26$ $0.93(0.58-1.47)$ and below <sup>b</sup> $1.15(0.75-1.74)$ $0.26$ $0.93(0.58-1.47)$ ol $0.0012$ $0.52$ $0.0001$ and below <sup>b</sup> $1.15(0.75-1.74)$ $0.52$ $0.0001$ and below <sup>b</sup> $0.1652$ $0.0001$ $0.66^{c}$ and below <sup>b</sup> $0.1652$ $0.0001$ $0.66^{c}$ and below <sup>b</sup> $0.1652$ $0.1062$ $0.0001$ and $0.166^{c}$ $0.166^{c}$ $0.166^{c}$ and $0.166^{c}$ $0.166^{c}$ $0.166^{c}$ and $0.166^{c}$ $0.166^{c}$ $0.1001$ and $0.1001$ $0.166^{c}$ $0.1001$ and $0.106^{c}$ $0.166^{c}$ $0.166^{c}$ and $0.106^{c}$ $0.166^{c}$ $0.166^{c}$ and $0.166^{c}$ $0.166^{c}$ $0.166^{c}$ and $0.106^{c}$ $0.166^{c}$ $0.166^{c}$ an	) or older	2.35 (1.71–3.23)	<0.001	2.28 (1.58–3.30)	<0.0001
I.30 (1.03-1.63)0.0273I.31 (1.02-1.67)icity0.0020cI.31 (1.02-1.67)ic Whiteb0.0020c0.011800.81 (0.53-1.23)ic Whiteb0.74 (0.50-1.08)0.11800.81 (0.53-1.23)Icitino0.57 (0.42-0.76)0.00020.66 (0.47-0.93)Icitino0.57 (0.42-0.76)0.00020.66 (0.47-0.93)Icitino0.57 (0.42-0.76)0.00020.66 (0.47-0.93)Icitino0.57 (0.51-1.20)0.260.93 (0.58-1.47)Icitino0.58 (0.51-1.20)0.260.93 (0.58-1.47)Icitino0.57 (0.52-1.74)0.560.0001Iciting belowb1.15 (0.75-1.74)0.520.0001Iciting belowb1.15 (0.75-1.74)0.520.0001Iciting belowb1.15 (0.75-1.74)0.520.0001Iciting belowb1.15 (0.75-1.74)0.521.12 (0.79-1.59)Iciting belowb1.15 (0.75-1.74)0.16521.39 (0.87-2.00)Iciting belowb1.16 (0.88-2.10)0.16521.39 (0.87-2.00)Iciting belowb1.11 (0.80-1.54)0.551.12 (0.79-1.59)Iciting below1.11 (0.80-1.54)0.371.37 (0.92-2.03)Iciting below1.18 (0.82-1.69)0.371.37 (0.92-2.03)	ender				
i:30 (1.03-1.63)0.02731.31 (1.02-1.67)ic White0.0020c0.0020c1.31 (1.02-1.67)ic White0.0020c0.018000.81 (0.53-1.23)ic Black0.74 (0.50-1.08)0.11800.81 (0.53-1.23)Latino0.77 (0.42-0.76)0.00020.66 (0.47-0.93)1 Latino0.78 (0.51-1.20)0.260.93 (0.58-1.47)Anothe0.78 (0.51-1.20)0.260.93 (0.58-1.47)Anothe0.78 (0.51-1.20)0.260.93 (0.58-1.47)Anothe0.78 (0.51-1.20)0.260.93 (0.58-1.47)Anothe1.15 (0.75-1.74)0.260.93 (0.58-1.47)Anothe1.15 (0.75-1.74)0.520.0001cAnothe1.15 (0.75-1.74)0.520.0001cAnothe1.15 (0.75-1.74)0.520.0001Anothe1.15 (0.75-1.74)0.521.33 (0.87-2.00)Anothe1.16 (0.88-2.10)0.16521.39 (0.87-2.00)Anothe1.11 (0.80-1.54)0.551.12 (0.79-1.59)Anothe1.11 (0.80-1.54)0.551.33 (0.87-2.00)Anothe1.11 (0.80-1.54)0.551.33 (0.87-2.03)Anothe1.13 (0.82-1.69)0.371.37 (0.92-2.03)Anothe1.18 (0.82-1.69)0.371.37 (0.92-2.03)Anothe1.18 (0.82-1.69)0.371.37 (0.92-2.03)Anothe1.18 (0.82-1.69)0.371.37 (0.92-2.03)	aleb				
icity icity $0.0020^{\circ}$ iic White <sup>b</sup> $0.0020^{\circ}$ $0.0180^{\circ}$ $0.81 (0.53-1.23)$ iic Black $0.74 (0.50-1.08)^{\circ}$ $0.1180^{\circ}$ $0.66 (0.47-0.93)^{\circ}$ iic Black $0.57 (0.42-0.76)^{\circ}$ $0.002^{\circ}$ $0.66 (0.47-0.93)^{\circ}$ $0.78 (0.51-1.20)^{\circ}$ $0.26^{\circ}$ $0.93 (0.58-1.47)^{\circ}$ $0.78 (0.51-1.20)^{\circ}$ $0.26^{\circ}$ $0.93 (0.58-1.47)^{\circ}$ and below <sup>b</sup> $0.78 (0.51-1.24)^{\circ}$ $0.26^{\circ}$ $0.0001^{\circ}$ $0.66^{\circ}$ $0.0001^{\circ}$ and below <sup>b</sup> $0.115 (0.75-1.74)^{\circ}$ $0.52^{\circ}$ $0.0001^{\circ}$ bol $0.155 (0.68-2.10)^{\circ}$ $0.165^{\circ}$ $0.0001^{\circ}$ ion $0.66^{\circ}$ are $1.10 (0.80-1.54)^{\circ}$ $0.56^{\circ}$ $1.12 (0.79-1.59)^{\circ}$ are $1.10 (0.80-1.54)^{\circ}$ $0.55^{\circ}$ $1.12 (0.79-1.59)^{\circ}$ are $1.18 (0.82-1.69)^{\circ}$ $0.37^{\circ}$ $1.37 (0.92-2.03)^{\circ}$ are are $0.18 (0.82-1.69)^{\circ}$ $0.37^{\circ}$ $0.37 (0.52-2.03)^{\circ}$	smale	1.30 (1.03–1.63)	0.0273	1.31 (1.02–1.67)	0.0319
ic White <sup>b</sup> ic White <sup>b</sup> ic Black $0.74 (0.50-1.08) 0.1180 0.81 (0.53-1.23)$ Latino $0.57 (0.42-0.76) 0.0002 0.66 (0.47-0.93)$ 0.78 (0.51-1.20) 0.26 0.93 (0.58-1.47) 0.78 (0.51-1.20) 0.26 0.93 (0.58-1.47) and below <sup>b</sup> $-0.0001 c$ Not Applicable -0.0001 c Not	ace/Ethnicity		$0.0020^{\mathcal{C}}$		$0.1175^{C}$
ic Black $0.74 (0.50-1.08)$ $0.1180$ $0.81 (0.53-1.23)$ Latino $0.57 (0.42-0.76)$ $0.0002$ $0.66 (0.47-0.93)$ 0.78 (0.51-1.20) $0.26$ $0.93 (0.58-1.47)and belowb -0.0001c Not Applicable -0.0001c Not Applicable -0.0001c Not Applicable -0.0001c Not Applicable -0.0001c -0.0001c -0.0001c -0.0001 -0.0001c -0.0001$	on-Hispanic White <sup>b</sup>				
Latino $0.57 (0.42 - 0.76)$ $0.0002$ $0.66 (0.47 - 0.93)$ (32 missing) $0.78 (0.51 - 1.20)$ $0.26$ $0.93 (0.58 - 1.47)$ (32 missing) $-0.0001c$ Not Applicableand belowb $-1.15 (0.75 - 1.74)$ $0.52$ ool $1.15 (0.75 - 1.74)$ $0.52$ ool $1.15 (0.75 - 1.74)$ $0.52$ oot $2.23 (1.64 - 3.05)$ $<0.0001$ oot high school $0.58 - 1.05$ $<0.0001$ oot high school $0.56 c$ $1.12 (0.79 - 1.59)$ on $0.165 2$ $1.12 (0.79 - 1.59)$ ar $1.11 (0.80 - 1.54)$ $0.55$ ur $1.13 (0.82 - 1.69)$ $0.37$ ar $1.18 (0.82 - 1.69)$ $0.37$ urance $1.18 (0.82 - 1.69)$ $0.37$	on-Hispanic Black	$0.74\ (0.50{-}1.08)$	0.1180	0.81 (0.53–1.23)	0.32
(32 missing) $0.78 (0.51-1.20)$ $0.26$ $0.93 (0.58-1.47)$ (32 missing) $<0.0001c$ Not Applicable         and below <sup>b</sup> $1.15 (0.75-1.74)$ $0.52$ ool $1.15 (0.75-1.74)$ $0.52$ ool $1.15 (0.75-1.74)$ $0.52$ ool $1.15 (0.75-1.74)$ $0.52$ ool $1.15 (0.75-1.74)$ $0.52$ oot high school $2.23 (1.64-3.05)$ $<0.0001$ oot high school $2.23 (1.64-3.05)$ $<0.0001$ oot high school $2.23 (1.64-3.05)$ $<0.0001$ oot $2.23 (1.64-3.05)$ $0.66c$ ar $1.11 (0.80-1.54)$ $0.55$ $1.12 (0.79-1.59)$ ar $1.23 (0.82-1.69)$ $0.37$ $1.37 (0.92-2.03)$ ar $1.18 (0.82-1.69)$ $0.37$ $1.37 (0.92-2.03)$	ispanic or Latino	0.57 (0.42–0.76)	0.0002	0.66 (0.47–0.93)	0.0174
(32 missing) $< 0.0001c$ Not Applicable         and below <sup>b</sup> $= 1.15 (0.75-1.74)$ $0.52$ ool $1.15 (0.75-1.74)$ $0.52$ ool $1.15 (0.75-1.74)$ $0.52$ oot high school $2.23 (1.64-3.05)$ $< 0.0001$ ost high school $2.27 (1.58-3.26)$ $< 0.0001$ ost high school $2.27 (1.58-3.26)$ $< 0.0001$ ar $2.27 (1.58-3.26)$ $< 0.0001$ in $2.27 (1.58-3.26)$ $< 0.0001$ ost high school $2.27 (1.58-3.26)$ $< 0.0001$ ar $0.66c$ $< 0.0001$ ar $1.16 (0.89-1.69)$ $0.56c$ ar $1.11 (0.80-1.54)$ $0.55$ $1.12 (0.79-1.59)$ ar $1.11 (0.80-1.54)$ $0.57$ $1.34 (0.87-2.04)$ ar $1.18 (0.82-1.69)$ $0.37$ $1.37 (0.92-2.03)$	ther	0.78 (0.51–1.20)	0.26	0.93 (0.58–1.47)	0.74
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	ducation (32 missing)		< 0.0001	Not Applicable	
Dol $1.15 (0.75 - 1.74)$ $0.52$ 1 $2.23 (1.64 - 3.05)$ $<0.0001$ oost high school $2.27 (1.58 - 3.26)$ $<0.0001$ ion $2.27 (1.58 - 3.26)$ $<0.0001$ ar $0.66c$ $0.66c$ ar $1.36 (0.88 - 2.10)$ $0.1652$ $1.39 (0.87 - 2.20)$ ar $1.36 (0.88 - 2.10)$ $0.1652$ $1.39 (0.87 - 2.20)$ ar $1.11 (0.80 - 1.54)$ $0.55$ $1.12 (0.79 - 1.59)$ ar $1.23 (0.83 - 1.83)$ $0.29$ $1.34 (0.87 - 2.04)$ ar $1.23 (0.82 - 1.69)$ $0.37$ $1.37 (0.92 - 2.03)$ arance $1.18 (0.82 - 1.69)$ $0.37$ $1.37 (0.92 - 2.03)$	ementary and below $b$				
I     2.23 (1.64–3.05)     <0.0001	iddle school	1.15 (0.75–1.74)	0.52		
oost high school         2.27 (1.58–3.26)         <0.0001           ion         0.66c            ar         1.36 (0.88–2.10)         0.1652         1.39 (0.87–2.20)           ur         1.11 (0.80–1.54)         0.55         1.12 (0.79–1.59)           ar         1.23 (0.83–1.83)         0.29         1.34 (0.87–2.04)           ar         1.18 (0.82–1.69)         0.37         1.37 (0.92–2.03)           urance         1.18 (0.82–1.69)         0.37         1.37 (0.92–2.03)	igh school	2.23 (1.64–3.05)	<0.0001		
ion 0.66° ar 1.36 (0.88–2.10) 0.1652 1.39 (0.87–2.20) tr 1.11 (0.80–1.54) 0.55 1.12 (0.79–1.59) ar 1.23 (0.83–1.83) 0.29 1.34 (0.87–2.04) 1.18 (0.82–1.69) 0.37 1.37 (0.92–2.03) urance	dvanced post high school	2.27 (1.58–3.26)	<0.0001		
ar 1.36 (0.88–2.10) 0.1652 1.39 (0.87–2.20) ur 1.11 (0.80–1.54) 0.55 1.12 (0.79–1.59) ar 1.23 (0.83–1.83) 0.29 1.34 (0.87–2.04) 1.18 (0.82–1.69) 0.37 1.37 (0.92–2.03) urance	evel of lesion		$0.66^{\mathcal{C}}$		$0.42^{C}$
umbar     1.36 (0.88–2.10)     0.1652     1.39 (0.87–2.20)       umbar     1.11 (0.80–1.54)     0.55     1.12 (0.79–1.59)       umbar     1.23 (0.83–1.83)     0.29     1.34 (0.87–2.04)       umbar     1.18 (0.82–1.69)     0.37     1.37 (0.92–2.03)	noracic b				
Imbar     1.11 (0.80–1.54)     0.55     1.12 (0.79–1.59)       umbar     1.23 (0.83–1.83)     0.29     1.34 (0.87–2.04)       1.18 (0.82–1.69)     0.37     1.37 (0.92–2.03)       Insurance     1.18 (0.82–1.69)     0.37     1.37 (0.92–2.03)	igh-Lumbar	1.36 (0.88–2.10)	0.1652	1.39 (0.87–2.20)	0.1649
umbar 1.23 (0.83–1.83) 0.29 1.34 (0.87–2.04) 1.18 (0.82–1.69) 0.37 1.37 (0.92–2.03) <b>Insurance</b>	id-Lumbar	1.11 (0.80–1.54)	0.55	1.12 (0.79–1.59)	0.54
1.18 (0.82–1.69) 0.37 1.37 (0.92–2.03) Insurance	ow-Lumbar	1.23 (0.83–1.83)	0.29	1.34 (0.87–2.04)	0.1801
ealth Insurance	acral	1.18 (0.82–1.69)	0.37	1.37 (0.92–2.03)	0.1189
	ealth Insurance				

Non-private	0.71 (0.57–0.90)	0.0045	0.79 (0.61–1.02)	0.0758
Current bladder management (excluding none $d$ )		${<}0.0001^{\mathcal{C}}$		$< 0.0001^{C}$
$\operatorname{CIC}\operatorname{only}{b$				
CIC + Rx	0.54 (0.42–0.69)	<0.0001	0.57 (0.44–0.74)	<0.0001
Other <sup>e</sup>	0.02 (0.00-0.18)	0.0003	0.02 (0.00–0.18)	0.0003
Variables	Univariate Odds Ratio (95% CI)	P-value	Multiple Odds Ratio (95% CI) <sup>d</sup>	P-value
Age of initial CIC		$0.66^{\mathcal{C}}$		0.69
12 and older $b$				
6 to 11	0.95 (0.67–1.36)	0.80	1.12 (0.76–1.65)	0.57
3 to 5	0.87 (0.62–1.23)	0.43	1.18 (0.80–1.74)	0.40
History of urology surgery				
4 oN				
Yes	1.44 (1.10–1.88)	0.0083	1.32 (0.99–1.77)	0.0557
Hydronephrosis degree		0.0979c	Not Applicable	
Noneb				
Mild (SFU1–2)	1.61 (1.08–2.40)	0.0185		
Moderate (SFU 3)	0.97 (0.48–1.98)	0.94		
Severe (SFU 4)	1.63 (0.59–4.55)	0.35		
Abbreviations: CIC – Clean Intermittent Catheterization, Rx = prescribed medication, SFU = Society of Fetal Urology grading system.	n, Rx = prescribed me	edication, SH	<sup>TU</sup> = Society of Fetal	Urology grading system.
$^{a}$ 1566 patients with non-missing data were included in the multiple regression model.	the multiple regressic	on model.		

J Pediatr Urol. Author manuscript; available in PMC 2023 October 01.

 $b_{
m Reference\ group.}$ 

 $\mathcal{C}_{ ext{Overall p-value.}}$ 

 $d_{\rm T}$ he None management group (n = 240) was excluded since all patients in this subgroup were incontinent.

encluded Crede, cystectomy, indwelling catheter, spontaneous void, vesicostomy, urostomy bag, urinary diversion, and one or more of them in combination.

Author Manuscript

Author Manuscript